Tonix製藥控股 TNXP 深 滬
等待開盤 09-30 09:30:00 美东时间
24.76
+0.550
+2.27%
華盛通- 最 高25.5199
- 今 開24.39
- 成交量 68.12万股
- 最 低 24.1694
- 昨 收 24.21
- 總市值 46.28亿
- 52周最高 130.00
- 市盈率 靜 --
- 換手率 0.36%
- 52周最低 6.76
- 委 比 -11.89%
- 總股本 1.87亿
- 歷史最高 13440000000.00
- 量 比 0.59
- 振 幅 5.58%
- 歷史最低 15.00
- 每 手 1
- 風險率 5.90%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Tonix Pharma Plans To Progress TNX-2900 Program For Treatment Of PWS Into Phase 2 Clinical Trial
Phase 2 randomized, double-blind, placebo-controlled trial planned to evaluate TNX-2900 in children and adolescents (ages 8 to 17.5 years) with Prader-Willi Syndrome under a cleared INDTNX-2900 granted Orphan Drug and Rare Pediatric Disease Designations by the FDA, providing the potential for a Priority Review Voucher upon approval
09-29 19:08
Tonix Pharmaceuticals Plans to Initiate Prader-Willi Syndrome Phase 2 Trial of TNX-2900 (Intranasal Potentiated Oxytocin) in 2026
Tonix Pharmaceuticals plans to advance TNX-2900, a magnesium-potentiated intranasal oxytocin formulation, into a Phase 2 clinical trial for children and adolescents with Prader-Willi Syndrome (PWS). TNX-2900 aims to improve receptor binding consistency and reduce off-target effects. The FDA has granted it Orphan Drug and Rare Pediatric Disease Designations, making Tonix eligible for a Priority Review Voucher upon approval. The trial will assess s...
09-29 11:00
Tonix Pharma Completes FDA Meeting for TNX-102 SL
Tonix Pharma ( ($TNXP) ) has shared an announcement. On September 18, 2025, Ton...
09-18 20:28
Tonix Pharmaceuticals Announces Positive Pre-IND Meeting with FDA for TNX-102 SL for the Treatment of Major Depressive Disorder
Tonix Pharmaceuticals Holding Corp. announced regulatory progress for TNX-102 SL as a potential depression treatment. The U.S. FDA provided positive feedback during a Type B Pre-IND meeting, supporting a supplemental new drug application to expand its use to major depressive disorder (MDD), citing exploratory evidence linking improved sleep quality to reduced depressive symptoms. TNX-102 SL, already FDA-approved for fibromyalgia, is a sublingual ...
09-18 12:00
Tonix Pharma Licenses Rights to Lyme Disease Antibody
The latest update is out from Tonix Pharma ( ($TNXP) ). On September 17, 2025, ...
09-17 19:29
Tonix Pharmaceuticals Announces In-licensing Phase 2/3-Ready Monoclonal Antibody Designed for Seasonal Prevention of Lyme Disease (TNX-4800)
Tonix Pharmaceuticals licencie le TNX-4800, un anticorps monoclonaux à longue durée d’action cible la protéine表面抗原A (OspA) de Borrelia burgdorferi responsable de la maladie de Lyme. Conçu pour une administration unique au printemps, il offre une protection tout au long de la saison des tiques. Un essai de phase 1 a confirmé la sécurité, la tolérance et une relation linéaire pharmacocinétique-pharmacodynamique-efficacité. L’objectif est de protége...
09-17 11:00
Tenax Therapeutics Announces European Patent Office Intention to Grant Patent Covering Use of Levosimendan in PH-HFpEF
<p align="justify">Tenax Therapeutics announced that the European Patent Office has notified its intention to grant a patent for intellectual property protection of TNX-103 (oral levosimendan) and other formulations of levosimendan, including its active metabolites, for use in pulmonary hypertension resulting from heart failure with preserved ejection fraction (PH-HFpEF). The patent, once granted, will provide protection in Europe through at leas...
09-16 11:00
Tonix Presents Clinical Data On Tonmya For Treatment Of Fibromyalgia At PAINWEEK Conference 2025; Phase 3 Data Support Q4 Launch Following PAINWEEK Showcase
Tonmya was approved by FDA on August 15, 2025 for the treatment of fibromyalgia and is the first new FDA approved treatment for fibromyalgia in over 15 yearsTwo pivotal Phase 3 studies demonstrated Tonmya significantly
09-08 19:04
Tonix Pharmaceuticals Presents Clinical Data on Tonmya™ for the Treatment of Fibromyalgia at PAINWEEK 2025
Tonmya, a sublingual cyclobenzaprine HCl tablet, was approved by the FDA on August 15, 2025, as the first new treatment for fibromyalgia in over 15 years. Studies showed Tonmya significantly reduced pain, improved sleep, and decreased fatigue compared to placebo, with a favorable tolerability profile. It is expected to be available in the fourth quarter of 2025. Tonmya works by targeting sleep disturbances linked to fibromyalgia symptoms through ...
09-08 11:00
Tonix Pharma Faces Setback Despite FDA Approval
Tonix Pharma ( ($TNXP) ) has fallen by -14.34%. Read on to learn why. Tonix Pha...
08-30 22:03
